For more than two decades, we have been developing the functionality
of our hydrogel products across multiple therapeutic areas in order
to deliver better quality of life to patients.
In addition to our patented technology, we work with international pharmaceutical and medical device
manufacturers which enables us to offer comprehensive treatment options.
By working with the scientific community and using our extensive expertise, we seek out
new areas where our unique hydrogel technology offers significant advantages
over existing technologies.
Approval of Bulkamid in the United States for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency in adult women who have SUI or stress predominant mixed incontinence.
Approval of Arthrosamid in Europe for the treatment of patients with knee osteoarthritis.
Arthramid Vet approved as a drug in Australia.
Arthramid Vet approved as a medical device in USA.
Approval of Arthramid Vet in New Zealand as a novel drug for the treatment of lameness in horses.
Commencement of a multi-centre, randomized, controlled clinical study of Arthrosamid for knee osteoarthritis.
Commencement of a prospective, open-label clinical investigation of Arthrosamid in knee osteoarthritis.
Publication of “Voice your Choice”, a study of women’s choice of surgery for primary stress urinary incontinence.
1 year results of randomised clinical trial of Bulkamid versus Tension-free Vaginal Tape (TVT) for 1st line surgical treatment of stress urinary incontinence (SUI) published
Distribution agreement with Mylan for Regurin XL extended for a further three years through mid-2022.
Publication in Clinical Orthopedics Advanced Research Journal, of the safety results for Arthrosamid for the treatment of knee osteoarthritis symptoms in a retrospective case series.
Publication in Research and Reports in Urology on particulate versus non-particulate bulking agents in the treatment of stress urinary incontinence.
Arthramid Vet licensed to Contura Vet for sale in the veterinary market.
Bulkamid granted vesicoureteral reflux (VUR) approval in Canada.
Prospective observational multicentred trial evaluating Bulkamid as a primary procedure for SUI commences in UK.
Contura’s manufacturing facility is granted EU GMP certificate.
Premarket approval for Bulkamid submitted to the FDA.
Worldwide rights to Mitem sold with distribution rights for Germany & Austria retained.
Contura undergoes management buyout.
2 year follow-up of Arthramid Vet clinical study reports with impressive results.
Arthramid Vet licensed to Antematter Ltd. for sale in the veterinary market.
Randomised clinical trial of Bulkamid versus Tension-free Vaginal Tape (TVT) for 1st line surgical treatment of stress urinary incontinence (SUI) commences in Finland.
Distribution rights licensed by the company for Cystistat in Germany and France for the symptomatic treatment of bladder conditions such as interstitial cystitis.
Following impressive results in the clinical study of Arthramid Vet, development of Arthrosamid commences for the treatment of osteoarthritis in the knees of humans.
Worldwide distribution rights for Bulkamid taken back from Ethicon and direct sale by the company commences.
North American randomised controlled trial of Bulkamid successfully completed with primary and secondary endpoints achieved.
Prospective controlled clinical study of Arthramid Vet successfully completed with primary and secondary endpoints achieved.
Clinical development of Arthramid Vet commences for the treatment of osteoarthritis in horses.
Worldwide rights acquired for Mitem, a mitomycin product for the treatment of bladder cancer.
Distribution rights licensed by the company for Regurin XL in the UK indicated for the treatment of overactive bladder.
Bulkamid granted ‘Investigational Device Exemption’ by the US Food and Drug Administration (FDA) allowing it to be used in a North American randomised controlled trial.
Contura signs agreement with Johnson & Johnson granting Ethicon, its women’s health subsidiary, exclusive worldwide distribution rights for Bulkamid.
Contura obtains ISO 13485 certificate, having demonstrated its ability to meet customer & regulatory requirements.
Aquamid Reconstruction granted CE-mark for larger volume corrections, rhinoplasty and lipoatrophy.
Bulkamid granted CE-mark for use in the treatment of female urinary incontinence.
Aquamid granted CE-mark for use in facial augmentation.